OncoSec's lead product candidate, ImmunoPulse IL-12, uses OncoSec's electroporation device to deliver a DNA-encoded interleukin-12
called tavokinogene telseplasmid, with the aim of reversing the immunosuppressive microenvironment in the tumor and engendering a systemic anti-tumor response against untreated tumors in other parts of the body.
Defects in the interferon-gamma and interleukin-12
Moreover, there was a decrease in inflammatory processes caused by an increase of the anti-inflammatory cytokine Interleukin-10 and a reduction of the pro-inflammatory cytokine Interleukin-12
after the retreat.
It acts as a cytokine inhibitor and targets interleukin-12
Through an AdV-based vector, Intrexon has already delivered the first clinically validated transcriptional gene switch utilising the RheoSwitch Therapeutic System to regulate the expression and concentration of a powerful cytokine, interleukin-12
, to treat cancer.
Interleukin-10 and interleukin-12
modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12
Mycobacterial, fungal and other opportunistic infections force the clinician to rule out a large list of conditions associated with secondary immunodeficiency as infectious agents (HIV, Herpesvirus, HTLV), drugs (steroids, immunosuppressants, biologics, chemotherapy), metabolic diseases (diabetes, renal failure, cirrhosis), malignancies (leukemia, lymphomas and solid tumors) and environmental conditions (radiation, heavy metals) (2) but even adult patients can have late onset primary genetic immunodeficiency disorders as chronic granulomatous disease, X-linked agammaglobulinemia, interleukin-12
receptor deficiency or interferongamma (IFN-?
Already with three active trials at leading institutions, two utilizing controlled gene therapy to express a powerful anti-cancer effector in interleukin-12
and the other incorporating the innovative non-viral Sleeping Beauty gene delivery system in chimeric antigen receptor T cell therapy (CAR-T) for advanced lymphoid malignancies, ZIOPHARM has positioned itself to meaningfully expand its clinical programs through the remainder of 2016 and over the course of 2017.
and interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis.
Its immunotherapy platform, ImmunoPulse, a naturally occurring protein with immune-stimulating functions focuses on the delivery of DNA-based interleukin-12
Induction of immunity and inflammation by interleukin-12